|

Ipilimumab Injection Clinical Trials

3 actively recruiting trials across 1 location

Also known as: Atezolizumab, BMS-734016, Bevacizumab, MDX-CTLA4, MDX010

Pipeline

Phase 2: 1Phase 2/3: 1

Top Sponsors

  • Wu Wenming1
  • NYU Langone Health1
  • Federation Francophone de Cancerologie Digestive1

Indications

  • Cancer3
  • Liver Disease1
  • Metastatic Tumor1
  • Unresectable Melanoma1
  • HCC - Hepatocellular Carcinoma1

Other2 trials

Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy
Phase 2/3
XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer
N/A

Los Angeles, California1 trial

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

The Angeles Clinic at Cedars Sinai

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.